Experimental: Tralokinumab
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Uncontrolled Asthma
Conditions
Uncontrolled Asthma
Trial Timeline
Oct 30, 2014 → Sep 21, 2017
NCT ID
NCT02194699About Experimental: Tralokinumab
Experimental: Tralokinumab is a phase 3 stage product being developed by AstraZeneca for Uncontrolled Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT02194699. Target conditions include Uncontrolled Asthma.
What happened to similar drugs?
4 of 10 similar drugs in Uncontrolled Asthma were approved
Approved (4) Terminated (0) Active (6)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02194699 | Phase 3 | Completed |
Competing Products
17 competing products in Uncontrolled Asthma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KHK4563 + KHK4563 + KHK4563 + Placebo | Kyowa Kirin | Phase 2 | 35 |
| HR17031 injection + insulin glargine | Jiangsu Hengrui Medicine | Phase 3 | 40 |
| Baxdrostat + Placebo | AstraZeneca | Phase 3 | 44 |
| Tralokinumab | AstraZeneca | Phase 3 | 40 |
| Baxdrostat + Placebo | AstraZeneca | Phase 3 | 40 |
| Benralizumab | AstraZeneca | Phase 3 | 40 |
| Baxdrostat + Placebo | AstraZeneca | Phase 2 | 35 |
| Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment E | AstraZeneca | Phase 1 | 29 |
| CIN-107 + Placebo | AstraZeneca | Phase 2 | 35 |
| Pegloticase + Methotrexate (MTX) | Amgen | Approved | 43 |
| Pegloticase | Amgen | Approved | 43 |
| Pegloticase + Methotrexate | Amgen | Phase 3 | 47 |
| Pegloticase + Methotrexate (MTX) | Amgen | Approved | 43 |
| Pegloticase with MTX | Amgen | Approved | 43 |
| abrocitinib | Pfizer | Pre-clinical | 30 |
| REGN5381 + Placebo | Regeneron Pharmaceuticals | Phase 2 | 27 |
| SAL0140 + SAL0140 placebo | Shenzhen Salubris Pharmaceuticals | Phase 1 | 36 |